NCT03084640View on ClinicalTrials.gov

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

July 2, 2021

Study Completion Date

September 30, 2021

Conditions
Malignant Melanoma
Interventions
DRUG

CMP-001

CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.

DRUG

Pembrolizumab

Pembrolizumab will be administered as per the schedule specified in the respective arms.

DRUG

CMP-001

CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.

Trial Locations (4)

15232

University of Pittsburgh Medical Center - Cancer Center, Pittsburgh

52242

University of Iowa Hospitals and Clinics, Iowa City

80045

University of Colorado, Aurora

90095

University of California, Los Angeles, Los Angeles

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03084640 - Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma | Biotech Hunter | Biotech Hunter